MoonLake (NASDAQ:MLTX) Stock

MoonLake

MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Macro,Shot,Of,Computer,Monitor,With,World,Stock,Market,Chart

News

Intraday Update

Movers

ACIC

ADMA

AEHL

AFRM

AKAM

ARRY

ARWR

BFRI

BROS

CDNA

CLNE

DCBO

DIOD

EVLV

FLNC

FLUX

FNKO

FROG

FWRD

GRPN

GRTS

GWAV

HGAS

INSG

IOVA

ITOS

LIDR

MGNX

MLTX

MVIS

NGVC

NTRA

NVAX

NVTS

ORGO

OUST

PEGY

PGNY

RVNC

RWAY

SKIN

SKYT

SOUN

SRTS

YELP

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Biotech

Equities

Health Care

Trading Ideas

General

ABBV

Results with MoonLake Immunotherapeutics&#39; Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors.

Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?

Small Cap

Markets

ARVN

CLDX

CRNX

DELL

EVBG

NTAP

OPRA

PTCT

RDNT

RGNX

RMBS

ROOT

RPAY

SANA

SMCI

XPOF

YMAB

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake Immunotherapeutics

WIIM

MoonLake Immunotherapeutics shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $62 to $82.

Goldman Sachs analyst Richard Law upgrades MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) from Neutral to Buy and raises the price target from $62 to $82.

Upgrades

Price Target

Analyst Ratings

Goldman Sachs Upgrades MoonLake to Buy, Raises Price Target to $82

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $100 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa, palmoplantar pustulosis, and axial spondyloarthritis, in addition to adult patients with HS and active psoriatic arthritis.&nbsp;
This increases the number of clinical trials led by MoonLake to ten and aligns with the plan to enroll over 3,000 patients in clinical trials with sonelokimab since the Company was founded in 2021.

MoonLake Immunotherapeutics Announced That Patients Have Been Screened In Three New Trials Across Three New Indications To Evaluate Sonelokimab To Treat Inflammatory Disease

MoonLake Immunotherapeutics Screens First Patients In Phase 3 IZAR Program

Wedbush analyst Yun Zhong assumes MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform rating and lowers Price Target of $73.

Initiation

Wedbush Assumes MoonLake at Outperform, Lowers Price Target of $73

Cantor Fitzgerald analyst Prakhar Agrawal reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on MoonLake

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $62 price target.

Needham Reiterates Buy on MoonLake, Maintains $62 Price Target

Wolfe Research analyst Andy Chen downgrades MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades MoonLake to Peer Perform

Needham analyst Serge Belanger maintains MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and lowers the price target from $66 to $62.

Needham Maintains Buy on MoonLake, Lowers Price Target to $62

MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.28) by 39.29 percent.

Earnings

Earnings Misses

MoonLake Q2 2024 Adj EPS $(0.39) Misses $(0.28) Estimate

Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform rating and announces Price Target of $104.

Oppenheimer Initiates Coverage On MoonLake with Outperform Rating, Announces Price Target of $104

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $66 price target.

Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

Press Releases

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Clear Street Launches Healthcare & Biotechnology Equity Research

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

CGEM

CRGX

DCTH

ELVN

ERAS

IMTX

IPSC

JANX

NUVB

PTGX

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

ImmunityBio

Immunovant

Janux Therapeutics

Kymera Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Soleno Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Zai Lab Limited - American Depositary Shares

Zai Lab

Goldman Sachs

HC Wainwright & Co.

Wedbush

Needham

Oppenheimer

Comments

MoonLake

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga